Clinical

Dataset Information

0

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence


ABSTRACT: The objective is to compare the efficacy and safety of masitinib at 4.5 mg/kg/day to placebo in the treatment of patients with localized, primary gastrointestinal stromal tumor (GIST) after complete surgery and with high risk of recurrence.

DISEASE(S): Gastro-intestinal Stromal Tumour,Gastrointestinal Stromal Tumor,Stromal Gastrointestinal Cancer,Tumor Del Estroma Gastrointestinal,Gastrointestinal Stromal Tumors

PROVIDER: 2156727 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2065554 | ecrin-mdr-crc
2009-09-05 | GSE17987 | GEO
2014-08-01 | GSE55521 | GEO
2016-12-27 | GSE69465 | GEO
2009-09-17 | E-GEOD-17987 | biostudies-arrayexpress
2010-10-14 | E-GEOD-22852 | biostudies-arrayexpress
2023-03-31 | GSE225819 | GEO
2014-08-01 | E-GEOD-55521 | biostudies-arrayexpress
| PRJNA600929 | ENA
2020-09-25 | GSE156715 | GEO